Halozyme Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for HALO, updated each market day.
HALO AI Sentiment
AI predicts Halozyme Therapeutics, Inc. stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Sector
Exchange
Market Cap
$7,947,256,044
Cap Tier
Employees
423
Headquarters
SAN DIEGO, CA
Listed Since
March 12, 2004
Website
HALO Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
HALO Volatility
Halozyme Therapeutics, Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
